Key Message {#sec1}
===========

In this first case series of 101 patients with COVID-19 referred to palliative care, input was brief; most patients died in less than three days. The most common symptoms were breathlessness and agitation, controlled in most cases using relatively small doses of opioid and benzodiazepine, delivered by subcutaneous infusion. To meet the rapidly growing need for palliative care, services must adapt. Training and guidance for nonspecialists will help ensure symptoms are addressed promptly.

Introduction {#sec2}
============

People diagnosed with COVID-19 have an estimated mortality of 1%--3%, with those with multimorbidity most at risk of dying.[@bib1] Estimates vary widely, but COVID-19 could directly cause up to 510,000 deaths in the U.K. and 2.2 million in the U.S.[@bib2] Although the clinical characteristics of COVID-19 patients have been described, the focus has been on risk factors for ICU admission and death.[@bib3] Data are lacking on the palliative care needs of people with COVID-19, including symptom burden and response to treatment, to help inform service planning for palliative care and hospice services in the U.K. and elsewhere. Here we describe the symptom burden, management, response to treatment, and outcomes for patients with COVID-19 referred to the palliative care teams in two large NHS hospital trusts in London, U.K.

Method {#sec3}
======

Design and Setting {#sec3.1}
------------------

This is a case series of 101 inpatients with confirmed COVID-19 infection, referred to the hospital palliative care teams at two large acute NHS Hospital Trusts in London, U.K. The two trusts comprise four hospitals and include a Highly Communicable Infectious Disease Unit. They serve populations who, during March 2020, had among the highest prevalence of COVID-19 in the U.K.

Data Collection and Analysis {#sec3.2}
----------------------------

Data were extracted from medical and nursing case notes by clinician-researchers (N. L., P. E., K. T., J. B., and S. E.). Variables included the following: baseline demographic and clinical characteristics; referral ward; comorbidities categorized by the Elixhauser Index[@bib4]; clinician-assessed palliative care phase of illness (stable, unstable, deteriorating, and dying or deceased) based on care needs and suitability of the current care plan[@bib5]; and Australia-modified Karnofsky Performance Status.[@bib6] Symptoms were identified from standardized palliative care notes. Symptom control medicines with doses were extracted from drug charts, and clinical impressions of effectiveness were determined based on documentation at follow-up (e.g., improved breathing, agitation, comfort). Descriptive analyses were performed using SPSS (V.24, Armonk, NY). Comparisons between groups were expressed as medians and interquartile ranges (IQRs) due to the data distribution.

Results {#sec4}
=======

For full demographic and other details, see [Table 1](#tbl1){ref-type="table"} . Between March 4 and March 26, 2020, 101 patients with COVID-19 were referred to palliative care, most frequently for end-of-life care or symptom control. Referrals rapidly increased from the first (*n* = 2) to the fourth week (*n* = 51). Sixty-four patients were men; the median age was 82 \[72--89\]. The Elixhauser Comorbidity Index was 6 \[2--10\]; the most common comorbidities were hypertension (54), diabetes (36), and dementia (31). Seventy-six patients had been admitted with COVID-19 and 25 were existing inpatients who developed COVID-19; median \[IQR\] days from admission to referral were 2 \[1--6\] and 16 \[7--30\] for these groups, respectively. At the time of referral, most patients (*n* = 95) were receiving ward-based care, with six on high-dependency or intensive care units (ICUs).Table 1Demographic and Clinical Characteristics, Palliative Care Contacts, and Outcomes of 101 Hospital Inpatients With COVID-19 Referred to Palliative CareCharacteristicMedian \[IQR\] or *n*Age, yrs82 \[72--89\]Sex, male:female64:37Elixhauser Comorbidity Index6 \[2--10\]Comorbidities Hypertension54 Diabetes36 Dementia31 Advanced/metastatic cancer25 Chronic pulmonary disease22 Renal failure21 Congestive heart failure18 Stroke/neurological disorder12 Peripheral vascular disorder4 Liver disease2AKPS20 \[10--20\] Missing15Level of care Ward-based care95 High dependency unit5 Intensive care unit1Reason(s) for referral to palliative care End-of-life care70 Symptom control41 Care planning4 Psychological support1Phase of illness Dying63 Unstable24 Deteriorating7 Stable1 Missing6Days of palliative care involvement2 \[1--4\]Palliative care contacts3 \[2--5\]Contacts by recipient Patient2 \[1--3\] Family1 \[0--1\] Hospital staff2 \[1--4\]Contacts by type In person3 \[1--4\] Telephone1 \[0--1\]Outcome Death75 Discharged13 Back to team10 Home2 To hospice1 Remains under palliative inpatient care13[^1][^2]

For full details of symptoms, drugs prescribed, and outcomes, see [Table 2](#tbl2){ref-type="table"} . The most prevalent symptoms were breathlessness, agitation, drowsiness, and pain. Twenty-four patients had symptoms of delirium. Ninety-six patients were prescribed "as needed" medication for symptom relief, and 58 patients were prescribed a subcutaneous infusion for symptom relief. Of the 37 patients who were prescribed morphine by subcutaneous infusion, the median final dose was 10 mg/24 hours. Fifty infusions contained midazolam, median final dose 10 mg/24 hours. The infusion was assessed as at least partially effective for 40/58 patients, while 13 patients died before effectiveness could be reviewed.Table 2Symptoms, Drugs Prescribed, and Drug Effectiveness in 101 Hospital Inpatients With COVID-19 Referred to Specialist Palliative CareSymptoms at Time of Referral*N* = 101 Breathlessness67 Agitation43 Drowsiness36 Pain23 Delirium24 Secretions11 Fatigue9 Fever9 Cough4 Other symptoms[a](#tbl2fna){ref-type="table-fn"}12Symptom relieving drugs given by subcutaneous infusion58 Morphine + midazolam23 Morphine + midazolam + glycopyrronium8Morphine alone4 Morphine + haloperidol1 Morphine + midazolam + haloperidol1 Fentanyl + midazolam9 Fentanyl + midazolam + glycopyrronium3 Alfentanil alone2 Alfentanil + midazolam4 Alfentanil + cyclizine1 Alfentanil + midazolam + haloperidol1 Midazolam alone1Median (range) dose/24 hours Morphine (mg)10 (5--30) Fentanyl (microgram)100 (100--200) Alfentanil (microgram)500 (150--1000) Midazolam (mg)10 (5--20) Glycopyrronium (microgram)1200 (600--2400) Haloperidol (mg)2 (1--2) Cyclizine (mg)50Clinical impression of effectiveness[b](#tbl2fnb){ref-type="table-fn"} Yes40 Unclear (patient died before follow-up)13 No5[^3][^4]

Patients spent a median \[IQR\] of 2 \[1--4\] days under the palliative care team and received 3 \[2--5\] contacts. As of March 30, 2020, patients had died (75), been discharged (13), or continued to receive palliative care input (13).

Discussion {#sec5}
==========

We provide the first report of characteristics, symptom management, and outcomes of patients with COVID-19 referred for hospital palliative care. The main symptom experienced by these patients was breathlessness, similar to that found earlier in the disease trajectory.[@bib7] In addition, we find patients near the end of life commonly experience agitation, while cough is infrequent. Time spent under the palliative care team was brief (median time 2 days), and symptom control with subcutaneous infusion was achieved in most cases using relatively small doses of opioid and benzodiazepine. Seventy-four percent of patients died.

Many services are currently facing dramatic increases in the number of people severely affected by COVID-19. In this series, the number of patients with COVID-19 referred for palliative care each week increased from 2 to 51 over four weeks. This is likely to necessitate changes in ways of working for palliative care teams such as an increase in remote patient assessment.

A proactive approach to symptom recognition, assessment, management, and escalation for people with COVID-19 is likely to be helpful.[@bib8] Providing brief and accessible ward-base teaching on managing breathlessness and agitation, with a low threshold for prescribing anticipatory medicines for those with prognostic uncertainty, can ensure symptoms are addressed promptly.[@bib9] Encouragingly, our data indicate that patients\' symptoms can be managed using opioids and benzodiazepines at low doses. Subcutaneous infusions were frequently used to achieve symptom control. It is essential that adequate stocks of equipment are available to provide symptom control medication for those affected by COVID-19, both in inpatient and community settings.

Agitation was common among our patients. A high level of psychological distress may result from rapid deterioration and be exacerbated by isolation due to visitor restrictions. Ways to mitigate against this include use of technology such as tablet computers to communicate with carers and friends, though this may not be practical for people near the end of life. Chaplaincy, social work, and psychology teams\' support are valuable.[@bib9]

The demographic characteristics of patients in this case series, predominantly older men with comorbidities, reflect global data on COVID-19 mortality risk.[@bib3] Hypertension and diabetes, the most frequent comorbidities in our patients, were risk factors for poor outcomes in a study of Chinese patients with COVID-19.[@bib10] A small proportion of patients in our case series were referred to palliative care for reasons other than COVID-19 but subsequently diagnosed as COVID-19 positive. It is important to acknowledge that their palliative care needs include both COVID-19 and non--COVID-19-related problems. In addition, there are likely to be knock-on impacts on non--COVID-19 patients resulting from the escalation in referrals, many of whom will receive less palliative care input as a result.

We included only patients referred to palliative care, and we have no information about the palliative care needs of other inpatients with COVID-19. We had few referrals from ICUs. Around 50% of patients with COVID-19 who are admitted to ICUs subsequently die and they are likely to have high palliative needs.[@bib11] ^,^ [@bib12] Information about symptoms was identified from the free-text notes, and we did not collect data on symptom severity. We report only on inpatient hospital patients and did not include community or inpatient palliative care units/hospices. The assessment of response to medication was subjective, and as the length of palliative care involvement was relatively short, there was not always sufficient time to assess effectiveness. Finally, this is an early case series and patterns are likely to change as the pandemic progresses.

Conclusion {#sec6}
==========

Patients severely affected by COVID-19 frequently experience symptoms and distress, and palliative care is an essential part of the response to this pandemic. Urgent research is needed to understand more about symptom prevalence and management, and how best to deliver palliative care to those dying in ICU and community settings. An international minimum data set for COVID-19 patients receiving palliative care would accelerate finding answers to these questions.
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[^1]: AKPS = Australia-modified Karnofsky Performance Status; IQR = interquartile range.

[^2]: Data are median \[IQR\] or *n*.

[^3]: Diarrhea (3), reduced oral intake (3), anxiety (2), seizures, ascites, incontinence, dysuria (1 each).

[^4]: Based on follow-up documentation, for example, improved breathing, agitation, comfort.
